Third-quarter revenue reaches 11 billion won
Up 11.1% year over year
Neuraceq and Vizamyl drive growth

Radiopharmaceutical company DuChemBio increased its third-quarter revenue, driven by expanded sales of its diagnostic agents for Alzheimer's disease. Demand for diagnostic tests translated into results even though only one anti-amyloid treatment is currently available for prescription in Korea.


DuChemBio's Third-Quarter Revenue Rises 11% on Growing Demand for Dementia Diagnostics View original image

On November 17, DuChemBio disclosed that its third-quarter revenue rose 11.1% year over year to 11 billion won. Operating profit remained at a similar level at 1.9 billion won. The company achieved this result while increasing its third-quarter research and development expenses by 260 million won from a year earlier. Operating profit for the first nine months of the year rose 14% to 5.1 billion won.


Growth was led by Neuraceq and Vizamyl, radiopharmaceuticals used to diagnose Alzheimer's disease. Combined revenue from the two products for the first nine months rose 32.7% to 7.1 billion won. Quarterly revenue also increased each quarter, from 2.1 billion won in the first quarter to 2.4 billion won in the second and 2.6 billion won in the third. Their share of total company revenue rose to 22.4% this year from 19.3% in the first nine months of last year. Of the 4 billion won increase in total company revenue over the same period, 1.8 billion won came from the two products.


The growth is attributed to expanded prescriptions of Leqembi, an Alzheimer's treatment whose active ingredient is lecanemab. Before Leqembi can be prescribed, an amyloid positron emission tomography (PET) scan must confirm the presence of amyloid buildup in the brain. As prescriptions increase, so does demand for scans. DuChemBio supplies the two products to 120 medical institutions nationwide. Sales for the first nine months totaled 16,959 doses (one dose per administration), up 33.6% from 12,690 doses in the same period a year earlier. The company operates a same-day supply system through five manufacturing facilities nationwide. In May, it signed a business agreement with the Korean Association of Neurology Clinics and is expanding regional testing hubs so that patients at neurology clinics can be referred to PET scan centers.


Sales of other diagnostic products also increased. ProstaSeek, a diagnostic agent for prostate cancer launched last December, has grown for three consecutive quarters, with revenue of 300 million won in the first quarter, 400 million won in the second and 500 million won in the third. Third-quarter revenue from FP-CIT, a diagnostic agent for Parkinson's disease, rose 9.3% year over year to 1.2 billion won.


Demand for diagnostic agents is expected to increase further. Kisunla, Eli Lilly's drug whose active ingredient is donanemab, is set to launch in Korea. Treatment can be stopped if a PET scan during treatment confirms that amyloid has been cleared. This means scans will be needed not only before treatment begins but also when treatment ends. In September, DuChemBio signed a 34.3 billion won investment agreement with Jeonbuk State and Jeongeup City to build a new production facility in the Jeongeup Advanced Science Industrial Complex. In preparation for Kisunla's launch, the company also plans to increase production capacity for Neuraceq and Vizamyl at the site. The first phase of the facility is targeted to begin operations in the second half of 2029.



DuChemBio CEO Kim Sangwoo said, "Demand for diagnostic tests has already translated into results, even in a market with only one treatment available." He added, "If the number of drugs available for prescription increases to two, demand for testing will grow as well."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing